about
BRAF-V600 mutations have no prognostic impact in stage IV melanoma patients treated with monochemotherapyThe price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab networkImprovement of overall survival in stage IV melanoma patients during 2011-2014: analysis of real-world data in 441 patients of the German Central Malignant Melanoma Registry (CMMR).Prognostic impact of tumour burden measured by quantitative real-time PCR from sentinel lymph nodes of melanoma patients: data from 10-year follow-up.Results of the first phase I/II clinical vaccination trial with direct injection of mRNA.Adjuvant treatment with vindesine in comparison to observation alone in patients with metastasized melanoma after complete metastasectomy: a randomized multicenter trial of the German Dermatologic Cooperative Oncology Group.Screening for skin cancer in bank and insurance employees: risk profile and correlation of self and physician's assessment.Determinants of survival in patients with brain metastases from cutaneous melanoma.Effectiveness of carboplatin and paclitaxel as first- and second-line treatment in 61 patients with metastatic melanomaPrognosis of sentinel node staged patients with primary cutaneous melanomaPembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial.Prognostic factors of melanoma patients with satellite or in-transit metastasis at the time of stage III diagnosis.Melanoma patients with unknown primary site or nodal recurrence after initial diagnosis have a favourable survival compared to those with synchronous lymph node metastasis and primary tumourSerum S100B, lactate dehydrogenase and brain metastasis are prognostic factors in patients with distant melanoma metastasis and systemic therapy.Systematic review of medical treatment in melanoma: current status and future prospects.Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials.Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma.Malignant melanoma: classification and staging of malignant melanoma.Diagnosis and treatment of cutaneous melanoma: state of the art 2006.Which melanoma patient carries a BRAF-mutation? A comparison of predictive models.Survival according to BRAF-V600 tumor mutations--an analysis of 437 patients with primary melanomaIncisional biopsy and melanoma prognosis: Facts and controversies.Oncogenetics of melanoma: basis for molecular diagnostics and therapy.Molecular genetic classification of difficult melanocytic tumors.Vemurafenib.Adjuvant treatment with pegylated interferon α-2a versus low-dose interferon α-2a in patients with high-risk melanoma: a randomized phase III DeCOG trial.Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy.Development of prognostic factors and survival in cutaneous melanoma over 25 years: An analysis of the Central Malignant Melanoma Registry of the German Dermatological Society.Melanoma staging: facts and controversies.Immune checkpoint blockade with concurrent electrochemotherapy in advanced melanoma: a retrospective multicenter analysis.Serial or Parallel Metastasis of Cutaneous Melanoma? A Study of the German Central Malignant Melanoma Registry.Age and gender are significant independent predictors of survival in primary cutaneous melanoma.Impact of 18F-FDG-PET/CT on surgical management in patients with advanced melanoma: an outcome based analysis.A dose-escalation and signal-generating study of the immunocytokine L19-IL2 in combination with dacarbazine for the therapy of patients with metastatic melanoma.Influence of (18)F-FDG PET/CT on therapy management in patients with stage III/IV malignant melanoma.Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab.Prospective evaluation of follow-up in melanoma patients in Germany - results of a multicentre and longitudinal study.A phase III, randomized, open label study to evaluate the safety and efficacy of imiquimod 5% cream applied thrice weekly for 8 and 12 weeks in the treatment of low-risk nodular basal cell carcinoma.Excision guidelines and follow-up strategies in cutaneous melanoma: Facts and controversies.Effective combination of photodynamic therapy and imiquimod 5% cream in the treatment of actinic keratoses: three cases.
P50
Q27852927-A53AACEC-279F-497A-A861-EF7C00212867Q28485085-7721782F-F8DC-489C-9172-52AE28F938A6Q31144246-9A91B6F8-329A-4044-8DA2-3C5050D18CD4Q31150157-58013266-6CC1-4D69-8564-DEB882D67E54Q33334868-53D9B209-7394-46E0-A2B7-3B5AC6BA3FB8Q33368047-795E76E0-869B-4949-8FAD-0748327C5745Q33456746-AF952874-78C1-416A-A535-1FE62FD22EB2Q33794890-300EA5AC-C1A3-402F-94A4-492A4EE7B4D9Q33831923-896B9C92-B8CD-4E58-8F88-3DEE09387119Q34140267-117E79E8-C59C-4743-A4E7-D29D2638D2DBQ34670965-F2D12F31-9645-4F5B-85E2-98CC0B95198AQ34702316-0E453362-F6A7-460D-B393-34B2FE78EEDAQ34794495-4EC5ED07-A0CC-424F-946E-307110B7F381Q35060623-C98E87D8-9DD8-45C8-B487-42AE55C6F145Q35584299-395020E0-3DD2-466D-A4B7-01ECB7566E0EQ35603108-4FCEDF30-24B9-4A13-A71C-ED98B12DBB5AQ36256712-F9524AEA-2C04-405F-993A-ED0A774F8BD6Q36361276-68D230BC-1F6A-43CE-9C7C-3BC68A6240CAQ36819323-B555D3DA-3FBC-4ABE-A353-E7C9F629207BQ37392661-5C23C146-DA94-4DAA-B4D1-4274E7F06BF9Q37514256-9AF75F7C-3B1E-4948-BE4E-A100DDBE1875Q37764496-7D2374A2-AFCE-48C0-A96E-65FDBCDD86E9Q37829775-487A7C8D-930F-4470-A8A3-17A151663611Q38110624-5A61E8EB-D2E3-4876-9FB2-E0C5F4737580Q38206457-A295FA8B-1E53-453D-96BF-D8B669F138B6Q38391496-9DA643E9-8B7E-46B1-9DE5-541A62CB23B9Q38753236-F53ACDF9-9F8B-448C-828D-9AB08ED97F55Q38925194-0F131B3E-6EC6-4FCB-B539-2EEE177DCF0AQ39207078-9AF33A70-7B4B-48AB-9C94-7CC15591799AQ39688544-35737198-F24C-40BA-BB64-3E45701CBAD7Q40111444-5C1848AD-47F5-4668-A5E3-E36749137DF6Q40119372-6FC75E7B-20E9-43AF-AB77-FC6903CBF484Q40286525-DFD1647B-5B3E-427C-BF21-7341BCEB7EEDQ40307989-A922010D-04F9-4442-9B52-8FEF6DA4DB58Q40524925-C645B27C-12C6-4A30-B378-18BFF5E6C4B3Q40964128-F549A1B3-9C69-4AB4-80C0-CF05321856D5Q41500730-C9288119-A732-4E9F-8757-9F827DF90B73Q42515208-53EEDB8F-9050-4437-8ECE-506C119284B4Q43028502-6FDDBCC2-8308-4BA3-8937-CD2186D26A4EQ43233963-48037117-4C8A-4B2F-9510-A3BEBC471053
P50
description
hulumtues
@sq
researcher
@en
ricercatore
@it
wetenschapper
@nl
հետազոտող
@hy
name
Thomas Kurt Eigentler
@ast
Thomas Kurt Eigentler
@en
Thomas Kurt Eigentler
@es
Thomas Kurt Eigentler
@nl
Thomas Kurt Eigentler
@sl
type
label
Thomas Kurt Eigentler
@ast
Thomas Kurt Eigentler
@en
Thomas Kurt Eigentler
@es
Thomas Kurt Eigentler
@nl
Thomas Kurt Eigentler
@sl
prefLabel
Thomas Kurt Eigentler
@ast
Thomas Kurt Eigentler
@en
Thomas Kurt Eigentler
@es
Thomas Kurt Eigentler
@nl
Thomas Kurt Eigentler
@sl
P214
P1053
K-8570-2015
P106
P1153
6603276213
P21
P214
P2798
P31
P3829
P496
0000-0003-0019-2770
P735
P7859
viaf-30587315